Compare CCAP & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCAP | VALN |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | France |
| Employees | 250 | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 418.9M | 495.5M |
| IPO Year | N/A | 2021 |
| Metric | CCAP | VALN |
|---|---|---|
| Price | $11.81 | $5.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 2 |
| Target Price | ★ $15.86 | $15.50 |
| AVG Volume (30 Days) | ★ 206.9K | 23.8K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | ★ 12.59% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $93.87 |
| P/E Ratio | $14.18 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.64 | $4.75 |
| 52 Week High | $16.04 | $12.25 |
| Indicator | CCAP | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 61.86 | 52.41 |
| Support Level | $10.83 | $5.10 |
| Resistance Level | $13.57 | $5.52 |
| Average True Range (ATR) | 0.26 | 0.13 |
| MACD | 0.09 | 0.05 |
| Stochastic Oscillator | 98.26 | 71.68 |
Crescent Capital BDC Inc is a business development company structured as an externally managed, closed-end, non-diversified management investment company. The company's primary investment objective is to maximize the total return to its stockholders in the form of current income and capital appreciation through debt and related equity investments. It will seek to achieve its investment objectives by investing in secured debt (including senior secured, unitranche, and second lien debt) and unsecured debt (including senior unsecured, mezzanine, and subordinated debt), as well as related equity securities of private U.S. middle-market companies.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.